Exact Sciences Corporation

NasdaqCM:EXAS Stok Raporu

Piyasa değeri: US$12.4b

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Exact Sciences Yönetim

Yönetim kriter kontrolleri 3/4

Exact Sciences' CEO'su Kevin Conroy, Apr2009 tarihinde atandı, in görev süresi 15.5 yıldır. in toplam yıllık tazminatı $ 16.12M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.5% maaş ve 93.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.39% ine doğrudan sahiptir ve bu hisseler $ 48.48M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 5.6 yıldır.

Anahtar bilgiler

Kevin Conroy

İcra Kurulu Başkanı

US$16.1m

Toplam tazminat

CEO maaş yüzdesi6.5%
CEO görev süresi15.5yrs
CEO sahipliği0.4%
Yönetim ortalama görev süresi3.8yrs
Yönetim Kurulu ortalama görev süresi5.6yrs

Son yönetim güncellemeleri

Recent updates

We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Sep 25
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Exact Sciences: Cost Optimization And Product Strength

Aug 18

Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Aug 14
Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Exact Sciences: Still No Reason To Own

Jun 11

Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive

Jun 02
Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Feb 23
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Jan 08
Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

Nov 15
Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

Oct 04
Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued

Aug 14
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued

Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt

Jun 15
Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt

Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)

Apr 26
Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)

We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Feb 23
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued

Jan 10
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued

CEO Tazminat Analizi

Kevin Conroy'un ücretlendirmesi Exact Sciences'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$175m

Mar 31 2024n/an/a

-US$240m

Dec 31 2023US$16mUS$1m

-US$204m

Sep 30 2023n/an/a

-US$282m

Jun 30 2023n/an/a

-US$432m

Mar 31 2023n/an/a

-US$517m

Dec 31 2022US$14mUS$510k

-US$624m

Sep 30 2022n/an/a

-US$716m

Jun 30 2022n/an/a

-US$735m

Mar 31 2022n/an/a

-US$745m

Dec 31 2021US$15mUS$963k

-US$596m

Sep 30 2021n/an/a

-US$793m

Jun 30 2021n/an/a

-US$829m

Mar 31 2021n/an/a

-US$720m

Dec 31 2020US$20mUS$499k

-US$824m

Sep 30 2020n/an/a

-US$327m

Jun 30 2020n/an/a

-US$165m

Mar 31 2020n/an/a

-US$136m

Dec 31 2019US$19mUS$792k

-US$213m

Sep 30 2019n/an/a

-US$216m

Jun 30 2019n/an/a

-US$221m

Mar 31 2019n/an/a

-US$219m

Dec 31 2018US$7mUS$696k

-US$175m

Sep 30 2018n/an/a

-US$143m

Jun 30 2018n/an/a

-US$124m

Mar 31 2018n/an/a

-US$119m

Dec 31 2017US$13mUS$633k

-US$114m

Tazminat ve Piyasa: Kevin 'ın toplam tazminatı ($USD 16.12M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 13.04M ).

Tazminat ve Kazançlar: Kevin şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Kevin Conroy (58 yo)

15.5yrs

Görev süresi

US$16,119,899

Tazminat

Mr. Kevin T. Conroy served as Independent Director of SomaLogic, Inc. since September 1, 2021, until January 2022. Mr. Conroy had served as an Independent Director of Adaptive Biotechnologies Corporation s...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Kevin Conroy
Chairman of The Board & CEO15.5yrsUS$16.12m0.39%
$ 47.6m
Jake Orville
Executive VP & General Manager of Pipelineno dataUS$3.67m0.0084%
$ 1.0m
Brian Baranick
Executive VP & General Manager of Precision Oncologyno dataUS$3.57m0.0076%
$ 945.6k
Aaron Bloomer
Chief Financial Officerless than a yearVeri yokVeri yok
Jorge Garces
Chief Science Officer3.5yrsVeri yokVeri yok
Nassar Nizami
Chief Information Officer1.8yrsVeri yokVeri yok
Megan Jones
Associate Manager of Investor Relationsno dataVeri yokVeri yok
Tim Caprez
Chief Compliance Counsel & VP9.8yrsVeri yokVeri yok
James Herriott
Senior VP2.8yrsVeri yok0.0060%
$ 739.2k
Sarah Condella
Executive Vice President of Human Resources7.4yrsUS$2.71m0.042%
$ 5.2m
Graham Lidgard
Emeritus Chief Science Officer3.8yrsUS$4.21mVeri yok
Ana Hooker
Chief Laboratory Officer9.3yrsUS$3.95mVeri yok

3.8yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: EXAS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Kevin Conroy
Chairman of The Board & CEO15.6yrsUS$16.12m0.39%
$ 47.6m
Daniel Levangie
Independent Director14.3yrsUS$408.75k0.015%
$ 1.9m
D. Coward
Director1.8yrsUS$1.47m0.030%
$ 3.7m
Katherine Zanotti
Independent Director15.5yrsUS$406.25k0.038%
$ 4.7m
Michael Barber
Independent Directorless than a yearVeri yok0.0029%
$ 364.7k
Paul Clancy
Independent Director3.6yrsUS$417.75k0.011%
$ 1.3m
Kathleen Sebelius
Independent Director5.6yrsUS$411.75k0.017%
$ 2.1m
Shacey Petrovic
Independent Director4.3yrsUS$401.25k0.012%
$ 1.5m
James Doyle
Lead Independent Director10.3yrsUS$442.75k0.030%
$ 3.7m

5.6yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: EXAS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.6 yıldır).